We are live on
!
Find out more
TD Asset Management Portfolio holdings
AUM
$115B
1-Year Est. Return
41.58%
This Fund
S&P 500
This Quarter
Est. Return
+8.84%
1 Year Est. Return
+41.58%
3 Year Est. Return
+119.77%
5 Year Est. Return
+143.7%
10 Year Est. Return
+448.76%
AUM
$82.9B
AUM Growth
+$1.82B
(+2.3%)
Cap. Flow
-$3.2B
Cap. Flow
% of AUM
-3.86%
Top 10 Holdings %
Top 10 Hldgs %
27.48%
Holding
1,503
New
58
Increased
633
Reduced
567
Closed
76
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Merck
MRK
|
+$256M |
| 2 |
State Street Energy Select Sector SPDR ETF
XLE
|
+$169M |
| 3 |
Eli Lilly
LLY
|
+$156M |
| 4 |
Franco-Nevada
FNV
|
+$115M |
| 5 |
NVIDIA
NVDA
|
+$115M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Canadian Pacific Kansas City
CP
|
+$990M |
| 2 |
Pfizer
PFE
|
+$226M |
| 3 |
Amazon
AMZN
|
+$224M |
| 4 |
Johnson & Johnson
JNJ
|
+$220M |
| 5 |
Alphabet (Google) Class C
GOOG
|
+$220M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.76% |
| 2 | Financials | 19.43% |
| 3 | Healthcare | 10.94% |
| 4 | Consumer Discretionary | 8.03% |
| 5 | Communication Services | 7.27% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
WAVC
901
DELISTED
Waverley Capital Acquisition Corp. 1
WAVC
| $2.61M | ﹤0.01% |
250,000
| – | – |
|
902
Cytokinetics
CYTK
$10.7B
| $2.6M | ﹤0.01% |
73,943
+22,800
| +45% | +$930K |
|
903
Zscaler
ZS
$26.4B
| $2.59M | ﹤0.01% |
22,198
-261
| -1% | -$31.3K |
|
904
Stewart Information Services
STC
$2.09B
| $2.59M | ﹤0.01% |
64,200
-23,400
| -27% | -$1.02M |
|
905
Boise Cascade
BCC
$3.04B
| $2.56M | ﹤0.01% |
40,500
-5,900
| -13% | -$409K |
|
906
Replimune Group
REPL
$1B
| $2.55M | ﹤0.01% |
144,563
+11,600
| +9% | +$276K |
|
907
Molson Coors Class B
TAP
$7.93B
| $2.53M | ﹤0.01% |
48,975
+95
| +0.2% | +$4.92K |
|
908
NRG Energy
NRG
$24.7B
| $2.53M | ﹤0.01% |
73,750
+14,068
| +24% | +$466K |
|
909
Payoneer
PAYO
$2.41B
| $2.52M | ﹤0.01% |
400,566
-11,360
| -3% | -$67.6K |
|
910
Boston Properties
BXP
$11.3B
| $2.51M | ﹤0.01% |
46,370
+466
| +1% | +$30.4K |
|
|
MRTX
911
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $2.51M | ﹤0.01% |
67,405
+13,300
| +25% | +$598K |
|
912
Mueller Water Products
MWA
$4.16B
| $2.48M | ﹤0.01% |
178,164
+14,000
| +9% | +$182K |
|
913
Strategic Education
STRA
$1.89B
| $2.48M | ﹤0.01% |
27,626
+23,026
| +501% | +$2.04M |
|
|
HTO
914
H2O America
HTO
$2.6B
| $2.48M | ﹤0.01% |
32,530
-360
| -1% | -$27.8K |
|
|
JBTM
915
JBT Marel
JBTM
$6.9B
| $2.47M | ﹤0.01% |
22,612
-1,672
| -7% | -$177K |
|
916
Bio-Rad Laboratories Class A
BIO
$8.91B
| $2.47M | ﹤0.01% |
5,157
-73
| -1% | -$34.2K |
|
917
Huntington Ingalls Industries
HII
$12.7B
| $2.47M | ﹤0.01% |
11,929
+1,281
| +12% | +$277K |
|
918
NeoGenomics
NEO
$2.09B
| $2.46M | ﹤0.01% |
141,400
+57,200
| +68% | +$815K |
|
919
Qiagen
QGEN
$8.73B
| $2.46M | ﹤0.01% |
50,917
-997
| -2% | -$50.7K |
|
920
PRA Group
PRAA
$672M
| $2.45M | ﹤0.01% |
62,918
+7,098
| +13% | +$279K |
|
921
Forward Air
FWRD
$484M
| $2.45M | ﹤0.01% |
22,700
| – | – |
|
922
Novanta
NOVT
$5.68B
| $2.45M | ﹤0.01% |
15,370
-346
| -2% | -$53.1K |
|
923
BlackLine
BL
$1.94B
| $2.43M | ﹤0.01% |
36,150
-290
| -0.8% | -$20K |
|
924
Pentair
PNR
$10.9B
| $2.42M | ﹤0.01% |
43,741
+524
| +1% | +$27.8K |
|
925
Elanco Animal Health
ELAN
$12.8B
| $2.41M | ﹤0.01% |
256,178
+124,796
| +95% | +$1.47M |
|
Similar funds
VAM
TD Asset Management's Q1 2023 Portfolio in Review
As of Q1 2023, TD Asset Management held 1,503 positions worth $82.9B, up 2.3% from $81B the previous quarter. Its ten largest holdings account for 27% of the portfolio.
TD Asset Management withdrew a net $3.2B in Q1 2023, closing 76 positions and reducing 567 holdings. Its most notable exit was Canadian Pacific Kansas City, an estimated $990M position sold in full.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 17% a quarter earlier, followed by Financials and Healthcare.
Against the trend, TD Asset Management opened a new position in Novo Nordisk worth $25.2M.
- TD Asset Management's largest Q1 2023 buy was Novo Nordisk: 316,140 shares worth $25.2M.
- TD Asset Management added most to Merck in Q1 2023, an estimated $256M increase.
- TD Asset Management's biggest Q1 2023 reduction was Pfizer, cutting an estimated $226M.
- TD Asset Management fully exited Canadian Pacific Kansas City in Q1 2023, selling an estimated $990M.
- TD Asset Management's ten largest holdings make up 27% of its $82.9B portfolio in Q1 2023.
- TD Asset Management opened 58 new positions and closed 76 in Q1 2023.
- TD Asset Management's portfolio value rose 2.3% quarter-over-quarter to $82.9B.
Based on TD Asset Management's 13F filing for Q1 2023, filed 10 May 2023.